Evidence map›Paper›PMID 41428759›Full record

ArticlePLoS computational biology2025

Abnormal vasculature reduces overlap between drugs and oxygen in a tumour computational model: Implications for therapeutic efficacy.

Romain Enjalbert, Jakub Köry, Timm Krüger, Miguel O Bernabeu

Abstract read
In one paragraph

Article in PLoS computational biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Romain EnjalbertCentre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0001-9685-5764
Jakub KörySchool of Mathematics and Statistics, University of Glasgow, Glasgow, United Kingdom.
Timm KrügerSchool of Engineering, Institute for Multiscale Thermofluidics, The University of Edinburgh, Edinburgh, United Kingdom.
Miguel O BernabeuCentre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom.ORCID 0000-0002-6456-3756

Funding

British Heart Foundation C-10180357Diabetes UK 20/0006221
6 · The paper itself

Abstract

The tumour microvasculature is abnormal, and as a consequence oxygen and drug transport to the tumour tissue is impaired. The abnormal microvasculature contributes to tumour tissue hypoxia, as well as to varying drug penetration depth in the tumour. Many anti-cancer treatments require the presence of oxygen to be fully efficacious, however the question of how well oxygen concentration overlaps with drug concentration is not elucidated, which could compromise the therapeutic effect of these drugs. In this work we use a computational model of blood flow and oxygen transport, and develop a model for an oxygen-dependent drug, T-DM1, to study the overlap of oxygen and drug concentration in tumour tissue, where we model both compressed and uncompressed vessels in the tumour. Our results show that, due to the compressed vessels present in tumours, areas of sufficient oxygen concentration for a drug to function overlap poorly with areas of sufficient drug concentration, covering 28% of the tumour tissue, compared to 82% in healthy tissue. The reduction in drug and oxygen overlap is due to the altered red blood cell dynamics through the abnormal microvasculature, and indicates that drug transport to tumours should not be considered independently of oxygen transport in cases where the drug requires oxygen to function.

Indexed as

Antineoplastic AgentsHypoxiaNeoplasmsNeovascularization, PathologicOxygenComputational BiologyHumansModels, BiologicalAntineoplastic AgentsOxygen

Identifiers

PMID41428759
PMCPMC12758810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.